INNOVADERM CRO IS NOW INDERO.

Episode 44: Donna D’souza & Audrey Miron – ACR Convergence 2026 Highlights

Indero

Indero

Team of Experts

 

 

Welcome to Phase Forward, your guide to clinical trial management in dermatology and rheumatology studies, where you will hear from operational experts and KOLs on everything from early phase, international markets, trial design, and much more. 

Our guests today are just back from ACR Convergence 2026 in sunny Orlando, Florida. Donna D’souza is a Clinical Scientist with a PhD in medical sciences where she examined the relationship between type 1 diabetes and skeletal muscle growth and repair. Before she joined Indero, Donna worked as a CRA at a large global healthcare company, and as a real-world evidence consultant, helping to lead and execute observational RWE studies. Welcome, Donna! 

We are also joined by a second guest. Audrey Miron has a Master of Science in Pharmacoeconomics and an MBA, and she’s been with Indero for nine years. As Director of Marketing, she leads the global marketing strategy, including for last week’s ACR Convergence 2026. Welcome, Audrey! 

 

Question: 

Heather 

Since Indero is a dual-focus CRO specializing in rheumatology and dermatology, obviously ACR is a big deal for us and a real highlight of the year. So, let’s talk about what went down at this year’s largest gathering of rheumatology industry and medical field folks that just happened. Donna, as a Clinical Scientist, I’m guessing maybe you checked out a few scientific sessions. What stood out for you? 

Answer: 

Donna 

You know, I had the great opportunity of looking at a few scientific sessions throughout the days that I was there. One of the key things that stood out to me was really the late-breaking trial results. There are lots of positive outcomes on combined biologic and GLP-1 trials. And this was in knee osteoarthritis as well as psoriatic arthritis. So that data to me was really exciting. 

 

Question: 

Heather 

I was going to ask you about GLP-1. I really was curious to know how much that came up. 

Answer: 

Donna 

Yeah, you know, we can’t really avoid GLP-1, especially in indications like arthritis and psoriatic arthritis. What I’ve seen based on the talks is that these therapies are proving to be far more than just weight management tools. Rheumatology care, I think, is really moving towards managing the metabolic inflammatory axis along with our standard disease-modifying therapies. 

 

Question: 

Heather 

Interesting. Any other hot topics that came up? 

Answer: 

Donna 

Yes, another great hot topic was the cell depletion therapies. There were lots of great sessions on the promise of CAR-T cell platforms. This is for indications like severe systemic lupus, myositis, as well as systemic sclerosis. The CAR-T cell platform data showed that these therapies don’t just induce deep immune resets, but they’re showing durable drug-free remission. But there is a caveat. I have to say there is a caveat to all of this. It’s really great data coming out that we saw, but the question remains on the logistics of whether we can implement these therapies beyond major academic hospitals. The next thing to watch is whether these therapies can be implemented at a larger scale. 

 

Question: 

Heather 

Was there anything else you learned that’s near and dear to your heart?  

Answer: 

Donna 

I attended a few talks on patient-centered outcomes. There’s some data that really highlighted the gap between these lab-defined remission outcomes and then the day-to-day patient quality of life. So, for example, what we’re seeing is on paper, the lab data showing that they’re hitting their targets, they’re achieving outcomes that they’re supposed to achieve. But when you ask the patient “How do you feel? How is it going?” they still have fatigue, they’re still not feeling great. So, I think the key takeaway from those sessions that we want to be able to evolve beyond clinical trial scores so that we can really target fatigue management as well as functional recovery. 

 

Question: 

Heather 

That really is happening more and more, isn’t it, where the patients’ voices are really getting out there, which makes a lot of sense. Fatigue for one, for sure. What about your overall impression of ACR 2026? What would that be, Donna? 

Answer: 

Donna 

There’s a lot to cover, but I think overall ACR 2026 really proved that the practice of rheumatology is evolving fast. We’ve got metabolic joint interventions, discussion of scalable cell therapies and also, as I just discussed, a stronger push for functional remission. So, I had a great time, learned a lot, and I’m really looking forward to seeing what other data comes out in the next months and weeks to come. 

 

Question: 

Heather 

Thanks for summarizing that for us. Now, Audrey, I believe that you had a chance to meet and listen to some pretty big-name KOLs on the topic of placebo response in rheumatology. Can you tell me about that? 

Answer: 

Audrey 

Yeah, of course. So, our team organized at ACR a breakfast event on placebo response in rheumatology trials. We had the opportunity to hear Dr. Joan T. Merrill. She’s a big name, a pioneer in lupus. We also had Dr. Andreas Kerschbaumer. He did share quite very surprising data. And we also had from Indero Pina D’Angelo, our Chief Scientific Officer, as well as Dr. Juan Ovalles, our Senior Director, Rheumatology. They were strong presenters and panelists. It was amazing. 

 

Question:  

Heather 

Why did you choose the topic of placebo response? 

Answer: 

Audrey 

We decided to go with placebo response because it remains a significant challenge in rheumatology. Our goal was to bring together everyone from the industry. So, we had a sample of scientific, clinical, medical, operational expertise, pretty much everyone, for a very open discussion about what are the factors, what may influence the trial outcomes, what are the questions that are triggering everyone, etc. 

 

Question: 

Heather 

Was it a lively, engaged crowd? 

Answer:  

Audrey 

Absolutely. Donna, you were here too. What did you think? 

Donna 

I thought it was fantastic. There were so many great questions from the audience, so many great discussions. I would urge everyone to check it out because I certainly learned a lot. So, I think a lot of people will get something great out of the placebo response event.  

 

Question: 

Heather 

With your own professional background, Audrey, I believe you had mentioned you were in Pharmacoeconomics. Was there something about the data that was discussed at this event that really resonated with your knowledge? 

Answer: 

Audrey 

Oh, absolutely, for sure. One thing I was very interested by was the socioeconomic context. In a nutshell, the analysis presented by Dr. Kerschbaumer, he looked at measures such as gross national income (GNI), patient’s healthcare expenses, and so on. And don’t get me wrong, my takeaway is not that geography and incomes directly cause a higher placebo response. The speakers were really clear that there’s an association, and that these are confounding factors that may not have been measured. But for me, the important message was that the socioeconomic data should not become a shortcut for excluding countries and/or patients. 

 

Question: 

Heather 

Interesting dimension, one that you don’t always necessarily hear when you’re doing this scientific discussion on placebo response. But I’m glad you told me about that. What about other topics like sites; were they discussed at all or patient recruitment? 

Answer: 

Audrey 

Absolutely. Sites were definitely one of the core discussion points. There are some aspects that were really important for everyone, and of course it was speed and signal quality. Especially for a new biotech company, they have pressure for timelines, financial and everything. But at the same time, if you recruit quickly, there might not be as much value if the study includes the wrong patients, as well as if we have inconsistent assessments. So really the goal is not to choose between speed and quality, but it’s really to design and run the trial so that the IP has a fair chance to show what it actually does, right? 

 

Question: 

Heather 

That’s a good way of putting it. Now, I know Dr. Joan Merrill is a giant in lupus. Were there any particular indications that Dr. Kerschbaumer focused on in his talk? 

Answer:  

Audrey 

Yes, although his talk was related to RA and PsA more specifically, after the presentations, there were very open-ended questions and discussions about rheumatology in general. So, I think that some of the aspects were data-driven, related to specific indications, but the discussion was not related to a specific indication. 

 

Question: 

Heather 

Wonderful. Thank you both for being here. It sounds like a really busy week. We were exhibitors at ACR Convergence 2026 and had lots and lots of meetings as well as this powerhouse event that you just described for us. Thank you very much. 

 

Now I know you’re both dog lovers. I have to ask, how did your dogs react when you flew home from Orlando a few days back? Donna? 

Answer: 

Donna 

Well, my dog, she acted like I just went to the store, so she was excited, but I don’t think she realized how long I was away for. But no, she was very happy to have me home and I was very happy to see her. 

 

Question: 

Heather 

Lovely. What about you, Audrey? 

Answer:

Audrey 

Well, my pup was nonstop happy spinning! 

 

Heather 

It’s nice when somebody misses you, right? Even if it is just your puppy. Well, thanks again. And as Donna had mentioned, this is now live on our website, the video recording that we just talked about. Take a watch.  

For more about Indero’s rheumatology CRO services, visit inderocro.com/rheumatology.

SHARE THIS POST

Subscribe to our Podcast.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Fields marked with * are required.